AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse 16:00:02 2024-05-24 EDT 5-day change 1st Jan Change
157.1 USD -0.76% Intraday chart for AbbVie Inc. -5.62% +1.35%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
AbbVie Completes Acquisition of Landos Biopharma MT
AbbVie Inc. completed the acquisition of Landos Biopharma, Inc. from a group of shareholders. CI
Strides Pharma Arm Gets US FDA's Approval for Generic Stomach Ulcer Drug MT
Cantor Fitzgerald Initiates AbbVie at Overweight Rating With $200 Price Target MT
ANALYST RECOMMENDATIONS : Walmart, Netflix, Abbvie, Delta... Our Logo
Transcript : AbbVie Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM
Medincell: share price falls after disappointing clinical study CF
AbbVie, Gilgamesh Pharmaceuticals Partner to Develop Therapies for Psychiatric Disorders MT
Medincell: share price rises on resumption of trading CF
AbbVie Says Canadian Regulator Expands Qulipta Indication to Cover Chronic Migraine MT
Daiwa Securities Adjusts Price Target on AbbVie to $171 From $190 MT
Health Canada Approves QULIPTA for the Preventive Treatment of Chronic Migraine in Adults CI
Medincell: listing suspended pending a press release CF
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent MT
Health Care Up on Growth Optimism -- Health Care Roundup DJ
BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating MT
Morgan Stanley Adjusts AbbVie's Price Target to $191 From $196 MT
Barclays Adjusts Price Target on AbbVie to $187 From $195 MT
Health Care Flat After Strong Earnings Week -- Health Care Roundup DJ
News Highlights : Top Company News of the Day - Friday at 5 PM ET DJ
News Highlights : Top Company News of the Day - Friday at 7 PM ET DJ
AbbVie Shares Close Down 4.6%, Sees Additional Humira Volume Erosion in 2Q DJ
News Highlights : Top Company News of the Day - Friday at 3 PM ET DJ
News Highlights : Top Company News of the Day - Friday at 1 PM ET DJ
Top Midday Stories: Google Announces First-Ever Dividend; Oil Giants Down on Earnings Misses; Second Norfolk Southern Union Backs Activist Investor's Board Candidates MT
Chart AbbVie Inc.
More charts
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
157.1 USD
Average target price
182.3 USD
Spread / Average Target
+16.05%
Consensus
  1. Stock Market
  2. Equities
  3. ABBV Stock
  4. News AbbVie Inc.
  5. AbbVie Says Phase 3 Interim Data Support Long-Term Efficacy, Safety of Migraine Drug